Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Combined With Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
NCT07049185Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University Cancer Hospital & Institute. Started Sep 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07049185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07049185.